AzurRx Acquisition of Issued and Outstanding Capital Stock of ProteaBio Europe SAS

Represented AzurRx BioPharma, Inc. in connection with the entering into of a Stock Purchase and Sale Agreement with Protea Biosciences Group, Inc., Protea Biosciences, Inc. and ProteaBio Europe SAS pursuant to which AzurRx acquired 100% of the issued and outstanding capital stock of ProteaBio Europe SAS.